Cyfuse Biomedical

Cyfuse Biomedical is a Japanese bioprinting company founded in 2010 that develops innovative 3D tissue-engineering technologies aimed at significantly advancing medical treatments. The company is best known for its Kenzan method of 3D bioprinting and its flagship product, the Regenova 3D bioprinter.

The Kenzan method is a scaffold-free technique where cell spheroids are skewered onto an array of needles in a pre-designed pattern. As the cells mature, they fuse together to form a 3D tissue construct without requiring any external scaffolding material. This gentle bioprinting approach results in a high percentage of viable cells and allows for the creation of complex, biomimetic tissue structures.

Cyfuse's Regenova bioprinter automates the Kenzan method, enabling the fabrication of intricate 3D tissue models with high resolution and reproducibility. The bioprinter has been utilized in various research projects, including the development of blood vessels, nerve tissues, functional liver constructs, and esophageal structures for transplantation.

In collaboration with academic institutions like the University of Tokyo and Kyoto University, Cyfuse has demonstrated the successful 3D bioprinting and implantation of tissues such as mini-livers, tracheas, and scaffold-free esophageal structures in animal models, showcasing the potential of its technology for regenerative medicine applications.